Trial
NCT02282917
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Massachusetts Eye and Ear Infirmary
Collaborators
Johns Hopkins University; Stanford University; Ohio State University; Nationwide Children's Hospital; Mayo Clinic
Condition
Vestibular Schwannoma
Intervention
AR-42
Why stopped
Drug manufacturing logistics; lack of access to drug supply
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-05